Editors' ChoiceCancer Immunotherapy

Papers of note in Science Translational Medicine 9 (385)

See allHide authors and affiliations

Science Signaling  18 Apr 2017:
Vol. 10, Issue 475, eaan4458
DOI: 10.1126/scisignal.aan4458

This week’s articles show that combining antiangiogenic therapy and immune checkpoint inhibition improves antitumor immunity.


Antitumor attack on two fronts

Schmittnaegel et al. and Allen et al. show that inhibiting angiogenesis alters the tumor-associated vasculature to facilitate the infiltration of cytotoxic T cells in multiple tumor models. Combining this antiangiogenic therapy with immune checkpoint blockade protected these T cells from tumor-induced suppression, suggesting that this combination strategy may enhance antitumor immunity in patients.

Highlighted Articles

Stay Connected to Science Signaling

Navigate This Article